Yorvipath is designed to parathyroid hormone exposure over 24 hours in patients with hypoparathyroidism.
- Sanofi to enhance neurology pipeline with new acquisition May 22, 2025
- BioNTech pledges major UK investment May 21, 2025
- New real-world data guidance could accelerate drug approvals May 20, 2025
- UK Government commits to long-term R&D funding May 19, 2025
- Novo Nordisk CEO to exit role May 16, 2025
- Takeda investigational drug shows efficacy in narcolepsy May 15, 2025
- Biogen Files Suit Against Neurimmune Over Rights to Bispecific Antibody May 21, 2025
- HyClone Seeks to Quash Amgen’s Subpoena Issued in Amgen/Accord Denosumab BPCIA Litigation May 21, 2025
- Regeneron Awarded $407 Million in Amgen Antitrust Suit May 19, 2025
- Teva and Alvotech Announce FDA Approval of Interchangeability for SELARSDI (ustekinumab-aekn) with STELARA (ustekinumab) May 16, 2025
- Join Us! The Future of Biotech Regulation Webinar May 16, 2025
- How the IRA’s Part B Coinsurance Inflation Adjustments Can Raise Seniors’ Drug Costs May 21, 2025
- What’s Next for Retail Pharmacy: Data, Debate, and Disruption (NEW Live Video Webinar) May 20, 2025
- Resetting the Walk-Away Price: How GoodRx Data Reveals New Realities of Prescription Abandonment May 16, 2025
- How Large PBMs Make Money Today: A 2025 Drug Channels Update May 13, 2025
- From Barriers to Bridges: Rethinking Medication Access for 2025 May 9, 2025
- Follow the 340B Dollar: Senator Cassidy Exposes How CVS Health and Walgreens Profit as 340B Contract Pharmacies May 6, 2025
- Claritas Rx’s Webinar: Achieve Specialty Pharma Success with AI: Enhance Care, Elevate Fill Rates by 20% and Improve Patient Adherence May 5, 2025